Effect of a single dose of escitalopram on serotonin concentration in the non-human and human primate brain.
Selective serotonin reuptake inhibitors (SSRIs) are widely prescribed for treatment of psychiatric disorders. The exact mechanism underlying the clinical effects of SSRIs remains unclear, although increased synaptic serotonin concentrations have been hypothesized to be an initial step. [¹¹C]AZ10419369 is a novel 5-HT(1B) receptor selective radioligand, which is sensitive to changes in endogenous serotonin concentrations. To assess whether a single dose of the SSRI escitalopram affects endogenous serotonin concentrations in serotonergic projection areas and in the raphe nuclei (RN), three cynomolgus monkeys and nine human subjects underwent PET examinations with [¹¹C]AZ10419369 at baseline conditions and after escitalopram administration. In monkeys, the binding potential (BP(ND)) was significantly lower post dose compared to baseline in dorsolateral prefrontal cortex, occipital cortex, thalamus, midbrain and RN (p < 0.05). In humans, the BP(ND) tended to decrease in RN post dose (p = 0.08). In all serotonergic projection areas, the BP(ND) was conversely higher post dose compared to baseline. The increase was significant in a combined region of all projection areas (p = 0.01) and in occipital and temporal cortex (p < 0.05). SSRIs are generally assumed to elevate endogenous serotonin concentrations in projection areas, evoking the antidepressant effect. In the present study, a single, clinically relevant, dose of escitalopram was found to decrease serotonin concentrations in serotonergic projection areas in humans. Hypothetically, desensitization of inhibitory serotonergic autoreceptors will cause the serotonin concentration in projection areas to increase over time with chronic administration. Thus, the findings in the present study might aid in understanding the mechanism of SSRIs' delayed onset of clinical effect.
Department of Clinical Neuroscience, Karolinska Institutet, Center for Psychiatric Research, Karolinska University Hospital, Stockholm, Sweden. Magdalena.Nord@ki.se
Magdalena
M
Nord
Sjoerd J
SJ
Finnema
Christer
C
Halldin
Lars
L
Farde
D000328:Adult; D000818:Animals; D001578:Benzopyrans / Q000493:pharmacokinetics; D001921:Brain / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000378:metabolism*; D015283:Citalopram / Q000097:blood / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D000882:Haplorhini; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D009025:Morpholines / Q000493:pharmacokinetics; D010879:Piperazines / Q000493:pharmacokinetics; D049268:Positron-Emission Tomography; D011485:Protein Binding / Q000187:drug effects; D012701:Serotonin / Q000378:metabolism*; D017367:Selective Serotonin Reuptake Inhibitors / Q000097:blood / Q000494:pharmacology*; D013997:Time Factors; D055815:Young Adult
D001578:Benzopyrans; D015283:Citalopram; D009025:Morpholines; D010879:Piperazines; D012701:Serotonin; D017367:Selective Serotonin Reuptake Inhibitors; C530629:5-methyl-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid (4-morpholin-4-yl-phenyl)amide